Silence Therapeutics
Silence Therapeutics (Nasdaq:SLN[1]) is a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need. Formed in 1994 as a publicly traded drug research and development company, Silence Therapeutics has offices in London, New Jersey and Berlin, with its corporate headquarters in Hammersmith, London.
 | |
| Type | Public (Nasdaq: SLN) |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 1994 |
| Headquarters | Hammersmith, London |
Number of employees | 120 |
| Website | www.silence-therapeutics.com |
Profile
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address rare hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others.
Partnerships
Silence Therapeutics has multiple partnerships with other pharmaceutical companies, such as AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others.
